Harcharan Gill

Back to Profile

Publication Details

  • Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.

    King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC. Int J Radiat Oncol Biol Phys. 2009; 73 (4): 1043-8

    The radiobiology of prostate cancer favors a hypofractionated dose regimen. We report results of a prospective Phase II clinical trial of stereotactic body radiotherapy (SBRT) for localized prostate cancer.

    PubMedID: 18755555

Stanford Medicine Resources:

Footer Links: